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SteroidsThe molecular chaperone Hsp90 is abundant, ubiquitous, and catholic to biological processes in eukaryotes,
controlling phosphorylation cascades, protein stability and turnover, client localization and trafﬁcking, and
ligand–receptor interactions. Not surprisingly, Hsp90 does not accomplish these activities alone. Instead,
an ever-growing number of cochaperones have been identiﬁed, leading to an explosion of reports on their
molecular and cellular effects on Hsp90 chaperoning of client substrates. Notable among these clients are
many members of the steroid receptor family, such as glucocorticoid, androgen, estrogen and progesterone
receptors. Cochaperones typically associated with the mature, hormone-competent states of these receptors
include p23, the FK506-binding protein 52 (FKBP52), FKBP51, protein phosphatase 5 (PP5) and cyclophilin
40 (Cyp40). The ultimate relevance of these cochaperones to steroid receptor action depends on their phys-
iological effects. In recent years, the ﬁrst mouse genetic models of these cochaperones have been developed.
This work will review the complex and intriguing phenotypes so far obtained in genetically-altered mice and
compare them to the known molecular and cellular impacts of cochaperones on steroid receptors. This article
is part of a Special Issue entitled: Heat Shock Protein 90 (HSP90).
© 2011 Elsevier B.V. All rights reserved.1. Introduction
The discovery of steroid receptors as major clients of Hsp90 oc-
curred in the early 80s, ﬁrst for the glucocorticoid receptor (GR) [1],
followed in rapid succession by the progesterone (PR), estrogen
(ER), androgen (AR) and mineralocorticoid (MR) receptors [2,3].
Since then, a variety of Hsp90 cochaperone proteins have been de-
scribed as components of steroid receptor complexes. These include
cochaperones involved in the early stages of steroid receptor complex
assembly and maturation, such as Hip, Hop, Bag-1 and Hsp40; those
involved in turnover and quality control of client proteins, such as
CHIP; and those found in the mature, hormone-competent binding
states of the receptors, such as FKBP51, FKBP52, Cyp40 and PP5. [For
comprehensive reviews of chaperones and SRs, see Refs. [4,5]]. It is
typically assumed that Hsp90 machinery serves to chaperone only
the steroid (type 1) branch of the nuclear receptor family, since the
archetypical type 2 members, such as thyroid (TR) and retinoic acid
(RAR) receptors, do not bind Hsp90 [6]. However, there are recent re-
ports of Hsp90 interaction with the peroxisome proliferator-activated
receptors, PPARα, PPARδ, and PPARγ [7,8], aryl hydrocarbon receptor
(AhR) [9], constitutive androstane receptor (CAR) [10], pregnane X
receptor (PXR) [11] and vitamin D receptors (VDR) [12]. Thus, it ishock Protein 90 (HSP90).
l rights reserved.likely that the chaperone actions of Hsp90 machine will be essential,
not only for proper functioning of the steroidal endocrine system, but
for metabolic processes, as well. Deciphering the contribution of the
Hsp90 machinery to physiology will obviously require, not one, but
multiple genetic mouse models, subjected to diverse endocrine and
metabolic stimuli and stresses. This effort is in its infancy, but impor-
tant lessons are already emerging. This review will attempt to put
these early reports in context by comparing the known molecular
and cellular effects of each chaperone on steroid action to observed
effects in vivo. [Note: a mouse genetic model of Cyp40 has not yet
been described. Therefore, Cyp40 will not be covered in this review.]
2. Chaperoning steroidal endocrinology—The overarching
questions
Prior to the discovery of steroid receptor-associated cochaperones,
the role of Hsp90 on steroidal biology seemed simple, as its main
function appeared to be the protection of the receptors from degrada-
tion and promotion of the hormone-binding function. The latter role
is consistent with the ATP-driven pincer or ratchet function of
Hsp90 dimers that imparts conformational changes to client proteins
[13,14]. Indeed, the GR ligand-binding domain is particularly depen-
dent on this Hsp90 function for its hormone responsiveness [15,16].
Thus, the prediction at the time would have been that Hsp90 serves
to regulate the sensitivity of organs to glucocorticosteroids (GCs).
With the discovery of cochaperones that bind mature steroid receptor
heterocomplexes, this prediction became too simplistic. The ﬁrst SR
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[18], Cyp40 [19], PP5 [20], and most recently FKBPL [21]. These pro-
teins directly bind Hsp90 via their respective tetratricopeptide repeat
(TPR) domains, entering into SR complexes at the ﬁnal stage of as-
sembly. Interestingly, because the Hsp90 dimer generates only one
TPR acceptor site [4], this means that multiple, distinct steroid recep-
tor heterocomplexes must exist in vivo based on TPR protein compo-
sition. These observations pose several overarching questions. Does
each TPR protein have a unique role in steroid receptor signaling?
Are these unique roles the same across all steroid receptors? Or do
some TPRs preferentially regulate one receptor over another? Last
and most important, do the TPRs selectively control steroidal physiol-
ogy? Partial answers to all of these questions are emerging.
3. Hsp90
3.1. Molecular actions and predicted endocrinology
To date, chaperoning by the Hsp90 machinery has been attributed
to all classical steroid receptors, several additional nuclear receptors,
AhR, and more recently PPARα and PPARγ. On this basis alone, the
predicted roles of Hsp90 in steroidal endocrinology are expected to
be profound and widespread, most likely controlling processes such
as fertility and reproduction, sexual differentiation and organogene-
sis, and lipid and drug metabolism. Yet proof of these predictions in
mouse models has been elusive due to the ubiquitous and pleiotropic
actions of Hsp90 in numerous other cellular processes. By most ac-
counts, Hsp90 comprises 1–2% of total cellular protein in unstressed
mammalian cells, rising to 4% following stress. Estimates of Hsp90 cli-
ent substrates are now approaching 300 [see Picard laboratory web-
site for comprehensive list of Hsp90 interactors: http://www.picard.
ch/downloads/downloads.htm]. Not surprisingly, early cell-based ef-
forts to eliminate Hsp90 expression typically resulted in cell death.
A notable exception was achieved in yeast, when Picard and col-
leagues were able to obtain a viable strain with 20-fold reduction of
Hsp90 [22]. In this strain, steroidal activation of GR transcriptional ac-
tivity was severely reduced. On the whole, however, the conventional
wisdom has been that ablation genetics of Hsp90 isoforms in the
mouse would be a biological dead end, or an uninterpretable morass.
Luckily, conventional wisdom is often wrong.
3.2. The unexpected divergent phenotypes of Hsp90α and β knockout
mice
In contrast to yeast, mammalian Hsp90 is encoded by two genes,
Hsp90α and Hsp90β, which are thought to be functionally similar
and redundant [23]. Their primary amino acid sequences are 86%
identical and they are mutually expressed in all tissues of the
mouse, with the exception of heart and muscle, which have greatly
reduced levels of Hsp90α compared to Hsp90β [24]. Although
Hsp90β is constitutively expressed, Hsp90α expression is highly-
inducible by heat shock and other forms of stress [23]. Most in vitro
studies show that each isoform displays the same preferences for
cochaperones and clients, with the exception that some client sub-
strates, such as c-Src and A-raf, preferentially bind Hsp90α following
heat shock [25]. However, some cellular processes appear to speciﬁ-
cally require Hsp90α, such as caspase-2 activation [26], maturation
of metalloprotease 2 in the extracellular matrix and invasiveness of
some metastatic cancers [27]. Taken as a whole, these in vitro param-
eters would have predicted relatively similar phenotypes for mice de-
ﬁcient in Hsp90α or Hsp90β. Surprisingly, this was not the case. The
Hsp90β knockout mouse displays early embryonic lethality [28]. Yet,
the only defect identiﬁed in Hsp90α-deﬁcient mice occurs in adult
males which exhibit a failure of spermatogenesis [24]. In the case of
Hsp90β, lethality occurs at embryonic day 9, due to an inability of
the embryo to develop a placenta, leading to a failure of implantationand death within 24 h. This result is interesting in several ways. First,
although Hsp90β is ubiquitously expressed in the day 9 embryo, the
only discernible defect was a failure of placental development. Sec-
ond, the allantois layer responsible for the implantation defect in
these mutants also expresses Hsp90α, yet failure still occurred, sug-
gesting that Hsp90α cannot compensate for this crucial developmen-
tal step. In contrast to Hsp90β, both male and female Hsp90α
knockout mice are viable and phenotypically normal into adulthood,
with the exception of sterility in male mice [24]. The speciﬁc defect
in males appears to be an arrest of spermatogenesis at the pachytene
stage of meiosis I, possibly due to reduced levels of meiotic regulators
of chromosomal synaptonemal complexes. Yet, given the prominent
role of androgens in spermatogenesis and the overwhelming in
vitro evidence for Hsp90 control of AR, it seems likely that an AR de-
fect contributes to male infertility in these mice.
4. p23
4.1. Molecular actions and predicted endocrinology
The p23 cochaperone was ﬁrst isolated from PR and GR heterocom-
plexes [29,30]. Since then it has been shown to be a common compo-
nent of all steroid receptors and AhR, entering these complexes in the
ﬁnal stages of assembly of mature, ligand-competent receptors [for re-
view of SR assembly see refs. [31,32]]. In cell-free extracts, the binding
of p23 to Hsp90 requires the ATP-bound state of Hsp90 which serves
to stabilize the p23/Hsp90 interaction with SRs, promoting the
hormone-binding function and preventing SR degradation. Cell-based
studies, however, paint a more complicated picture with p23 being ei-
ther stimulatory [33] or inhibitory [34] of GR activity, stimulatory of
ER [35], and inhibitory of TR, AR and MR [33]. These facts alone make
predictions of its physiological contributions difﬁcult. Yet, p23 is also
reported to have enzymatic activity as a cytosolic prostaglandin E
synthase (cPGES) [36], and has recently been implicated in telomere
length maintenance by promotion of telomerase extension activity
[37]. Both of these potential functions appear to be intrinsic properties
of p23 not mediated by interaction with Hsp90.
4.2. Perinatal lethality of p23 null mice may be GR mediated
Because of its ubiquitous interaction with SRs, the p23 knockout
mice, if viable, were expected to have a severe phenotype. The ﬁrst
p23 null mouse was made by the Picard laboratory [38]. The null an-
imals exhibited perinatal lethality that principally results from defec-
tive lung development, characterized by markedly reduced airspaces
and reduced expression of surfactant genes. Null mice also showed
underdevelopment of whole-body skin. These phenotypes are re-
markably similar to the atelectatic lungs and skin defects seen in GR
null mice [39,40]. Like p23 null mice, defective lung development in
the GR KO mice also leads to perinatal lethality. Not surprisingly,
analysis of p23 KO mouse embryonic ﬁbroblast (MEF) cells showed
reduced GR activity. Two other laboratories have also generated p23
null mice that demonstrated abnormal skin, underdeveloped lungs,
reduced expression of GR markers and perinatal lethality [41,42].
The p23 KO mice generated by Nakatani and coworkers showed re-
duced levels of prostaglandin PGE(2) in lung tissue, suggesting that
the absence of prostaglandin E synthase activity of p23 may be a con-
tributing factor. However, a more recent study by the same laboratory
in p23 KO cells showed elevated secretion of PGE(2) into the media
due to decreased expression of a PGE(2) degrading enzyme [43]. In
the studies by Lovgren and coworkers [42], no effect of p23 deﬁciency
was found on prostaglandin biosynthesis in tissues or cells. Moreover,
mice with knockout of PGE(2) receptors, including the EP4 receptor
expressed in lung, have not manifested lung defects [44]. Therefore,
it is not likely that the purported cPGES activity of p23 could single-
handedly account for the lethal lung defect in null mice. Given the
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lung development [45], the more likely cause is abrogated GR respon-
siveness during this critical event in postnatal survival. It is also likely
that if p23 null mice could survive, other p23-regulated ligand re-
sponses in adult mice would be uncovered. Recently, transgenic
mice ubiquitously over-expressing p23 have been generated [46].
Early results in the transgenics showed abnormal kidney function
similar to human hydronephrosis that correlated with increased ex-
pression of cytochrome P450 genes typically regulated by AhR. This
approach, as well as the generation of tissue-speciﬁc ablation of
p23, will be necessary for full dissection of its contribution to
physiology.
5. FKBP52
5.1. Molecular actions and predicted endocrinology
FKBP52 is a TPR-containing immunophilin with peptidyl–prolyl
cis–trans isomerase (PPIase) activity that is inhibited by the binding
of FK506 [47]. It was ﬁrst discovered by Faber and colleagues as a
component of the untransformed PR complex [48] and has since
been found to interact with all SR receptors [17,49,50]. Numerous
cell-based studies uniformly point to FKBP52 as a positive regulator
of SR transcriptional activity [51–53], with the possible exception of
ER which appears to be less sensitive to its actions [54]. Interestingly,
FKBP52 is not a global regulator of SR transcriptional activity, as some
GR-regulated genes are not affected by the loss of this protein [55].
The nature and extent of SR- and gene-speciﬁc effects of FKBP52
await comprehensive gene array studies. Similarly, the exact mecha-
nism of its potentiating activity on SRs has remained elusive. Its in-
trinsic PPIase activity is not required for GR, since enzymatically
dead mutants of FKBP52 still exert positive effects on the GR [56].
However, full AR activity does require the PPIase function of FKBP52
[57]. The potentiation effect may be due to its role in controlling in-
tracellular trafﬁcking of SRs. Hormone-induced translocation of GR
and MR correlates with a swapping of FKBP51 for FKBP52 and con-
comitant recruitment of the motor protein dynein [53,58]. The intrin-
sic subcellular location of SRs may also be controlled by FKBP51 and
FKBP52, as GR complexes which primarily reside in the cytoplasm
of intact cells preferentially interact with FKBP51, while PR com-
plexes located in the nucleus preferentially bind to FKBP52 [59].
Thus, the overall positive effect of FKBP52 on SRs may simply result
from its ability to promote nuclear localization of receptors.
5.2. Tissue-speciﬁc regulation of organogenesis and fertility
Prior to generation of FKBP52nullmice, dramatic effects on steroidal
endocrinology were predicted, including embryonic/neonatal lethality
due to reduced GR activity, and reduced fertility due to defective PR ,
AR and ER responses. Interestingly, both of these overall effects have
been seen. FKBP52 null mice were independently generated by the lab-
oratories of Smith [57] and Shou [54]. Approximately 50% of the Smith
KO mice propagated on the C57BL/6J background were embryonic le-
thals, while the ~30% of the original Shou mice propagated on
129SvEv background died during development. However, recent back-
crossing of the Shou strain with C57BL/6J has increased the percent of
lethal embryos [60]. Although this suggests that genetic background
contributes to the penetrance of FKBP52 action, at present no other
cause for embryonic death has been identiﬁed.
In both strains of mice, surviving FKBP52 null animals grew into
healthy adults except for reduced fertility in males and females. In the
Smith strain, null males demonstrated ambiguous external genitalia
and greatly reduced (dysgenic) prostate mass [57]. Null Shou mice
also showed dysgenic prostate, but the genital defect was identiﬁed as
a cleft in the ventral surface of the penis, a common birth defect in
humans known as hypospadias [61]. Further studies by Shou andcolleagues during embryonic development showed that hypospadias
occurred at E18.5 due to a failure of fusion of epithelial cell layers at
the ventral aspect of the penis. Interestingly, in WT developing males
FKBP52 expression was highest in the lead epithelial cells destined to
make contact at the site of fusion. All of these properties pointed to a de-
fect of AR signaling as the underlying culprit. Using cells with knock-
down expression of FKBP52, the Smith laboratory showed reduced AR
transcriptional activity at reporter genes, and that AR activity required
the PPIase function of FKBP52 [57]. InMEF cells derived from FKBP52KO
mice, the Shou laboratory showed a similar loss of AR activity at report-
er genes and at endogenous AR-induced genes controlling sexual di-
morphism and cell growth [61,62]. Last and most important,
supplementation of gestating Shou strain WT female mice with testos-
terone resulted in partial rescue of the hypospadias defect in null male
embryos [62], demonstrating that FKBP52 KOmales do indeed have re-
duced androgen responsiveness in vivo.
FKBP52 null females from both strains showed remarkably similar
phenotypes. In each case, null females were found to be sterile from a
complete failure of the uterus to support implantation [54,63]. Lack of
uterine receptivity was primarily due to abrogation of PR responsive-
ness, as determined by reduced hormone activation of PR in FKBP52
KO MEF cells and by reduced expression of progesterone-induced
genes in mutant uteri. In contrast, the uterine estrogenic response was
unaffected in null females, as estradiol induction of uterine weight
and lactoferrin gene expression were normal. Because two isoforms of
PR are known to exist, PR-A and PR-B, Shou and colleagues tested
whether FKBP52 might speciﬁcally regulate one isoform over the
other [54]. Results showed a preference of PR-A for interaction with
FKBP52 and a greater inﬂuence of FKBP52 on PR-A activity in MEF
cells. This was conﬁrmed in vivo, as only PR-A induced uterine genes
(calcitonin and amphiregulin) but not a PR-B gene (histidine decarbox-
ylase) were reduced in null females. Interestingly, each strain also
showed little to no effect of FKBP52 loss on ovulation rates, even though
this response is also known to require progesterone stimulation. Simi-
larly, progesterone induction of mammary gland alveologenesis was
only marginally reduced in Shou strain null females [54]. Thus, like
male FKBP52 null mice, the role of FKBP52 in the control of female ste-
roidal physiology appears to be highly receptor- and tissue-speciﬁc.
Follow-up studies by the Dey laboratory have expanded our under-
standing of how FKBP52 contributes to uterine biology. Implantation
failure in null females was found to be dependent on genetic back-
ground and stage of pregnancy [64]. For example, progesterone supple-
mentation was able to rescue implantation in CD1 null females, but not
in null females on a mixed C57BL/129 background. Endometriosis is a
condition of ectopic growth of uterine endometrial cells that typically
arises from excessive estrogenic stimulation or insufﬁcient stimulation
by progestins. Not surprisingly, FKBP52 null femalesweremore suscep-
tible to ectopic endometrial growth, while human samples of endome-
triosis had greatly reduced levels of FKBP52 [65], showing that FKBP52
promotion of PR action is essential to protection against this condition.
Lastly, FKBP52 was also found to protect the uterus against oxidative
stress, in this case by a mechanism that does not involve PR, but rather
by FKBP52 effects on a unique anti-oxidant protein, peroxiredoxin-6
[66].
5.3. A positive regulator of hepatic GR-induced gluconeogenesis
Numerous cell-based studies have shown that FKBP52 is required for
full activity of GR. For this reason, a GR phenotype was expected in
FKBP52 null mice, perhaps even neonatal lethality. Although it is tempt-
ing to ascribe thehigh rate of embryonic lethals seen in FKBP52nullmice
to a failure of GR, at present no direct evidence for this exists. Certainly,
the FKBP52 null mice do not appear to die from the atelectasia typically
seen in GR KOmice. Instead, it is more likely that FKBP52 null mice have
subtle GR defects, such as reducedGC sensitivity at peripheral organs, es-
pecially under conditions of stress. This hypothesis was recently tested
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genic genes and by subjecting FKBP52 (+/−) mice to the dietary stress
of a high-fat diet [60]. FKBP52 (+/−) mice were more susceptible than
WT litter-mates to the adverse effects of this diet, including hyperglyce-
mia, hyperinsulinemia, and fatty liver (steatosis). Interestingly, the mu-
tant mice also showed elevated levels of circulating corticosterone but
reduced expression of hepatic gluconeogenic genes, suggesting a state
of GC resistance that arises, at least in part, from insensitivity of hepatic
GR. Under these conditions, it is likely that reducedGRhepatic gluconeo-
genic activity may actually exacerbate hepatic fatty buildup because the
excess 3-carbon compounds of the high-fat diet are shunted to lipogenic
pathways. These results are the ﬁrst in vivo data for alteration of GR-
regulated physiology in cochaperone-deﬁcient mice. Much is clearly
left to be discovered, as it is likely that FKBP52 modulates GR responses,
not only at other metabolic organs (e.g., muscle, adipose), but wherever
GR and FKBP52 are co-expressed.
6. FKBP51
6.1. Molecular actions and predicted endocrinology
Although FKBP51 is structurally similar to FKBP52, containing TPR
domains and PPIase activity that is inhibited by FK506, it tends to
have inhibitory effects on SRs, with the exception of ARwhere it is stim-
ulatory [67]. Not only is the FKBP51 interaction with PR and GR com-
plexes inhibitory of their respective activities, but each receptor will
upregulate FKBP51 expression in what appears to be a negative-feed-
back mechanism to suppress hyperactivity [68]. Thus, the reasonable
prediction in FKBP51 null mice has been for phenotypes resembling
GR or PR hypersensitivity. In contrast, AR-mediated physiology was
expected to be suppressed, similar to that seen in FKBP52 null males.
6.2. The FKBP1 paradox: no role in male fertility yet promotion of
prostate cancer cell growth
Detailed histological and fertility studies by the Smith, Dey and
Shou groups have yet to uncover any defects in male or female
FKBP51 null mice [57,61,63]. Although this was not that surprising
with respect to female fertility, where elevated PR-mediated re-
sponses might not lead to loss of function, it was surprising in
males. Several cell-based studies have demonstrated that FKBP51 is
essential for AR function, including its ability to bind hormone and
transcriptional activity [69–71]. Moreover, AR, like GR and PR, also di-
rectly upregulates expression of FKBP51, presumably as a feed-
forward mechanism to potentiate its activity [69,72–77]. In contrast
to its apparent neutrality in male fertility, FKBP51 is a powerful posi-
tive regulator of androgen-mediated growth of prostate cancer cells
[70,71]. In addition, in vivo xenograph studies in mice showed that el-
evated FKBP51 expression correlates with progression of prostate
cancer from the relatively benign androgen-dependent state to the
malignant androgen-independent state [75,78]. Lastly, analysis of
human prostate cancer tissues showed a remarkable correlation
with high levels of FKBP51 [71]. Taken as a whole, it may be that
FKBP51 is not an important regulator of AR-mediated sexual differen-
tiation and function, but may preferentially regulate AR-mediated cell
growth. Conﬁrmation of this hypothesis will require studies in older
null male mice with or without treatment to induce prostate cancer,
or the development of transgenic mice with prostate-speciﬁc over-
expression of FKBP51.
6.3. A contributor to the adverse neuroendocrine effects of chronic stress
Recently, FKBP51 has received a lot of attention for its potential
role in neuroendocrine control of behavior and the onset of psycho-
logical disorders, such as post-traumatic stress disorder (PTSD) and
major depression [79]. Historically, high levels of glucocorticoidshave been viewed as contributory to these disorders. Yet, evidence
now exists that high GC levels may reﬂect a state of GC resistance
that actually promotes increased sensitivity to psychosocial stress.
Not surprisingly, several studies of psychosocial stress have implicat-
ed genetic variations or increased expression of FKBP51 as a potential
cause [80–83]. This concept was recently tested in FKBP51 null mice
by Schmidt and colleagues [84]. Null mice subjected to three weeks
of chronic social stress showed a less vulnerable phenotype that in-
cluded a reduced response to and enhanced recovery from acute
stress episodes. Interestingly, stressed KO mice also showed reduced
adrenal gland weight and lower levels of basal corticosterone, indi-
cating that enhanced GR activity due to FKBP51 loss is either increas-
ing negative-feedback regulation of GC secretion, or enhancing
neurological GC responsiveness, or both.
6.4. Resistance to diet-induced adiposity in FKBP51 null mice?
With respect to metabolism, FKBP51 null mice would be expected to
have elevated GR activity, leading to hyperglycemia, muscle wasting and
excess lipolysis, especially at peripheral adipose depots. To date no stud-
ies onmetabolism in the FKBP51mice have been published.We have re-
cently undertaken such a study by subjecting FKBP51 KO mice to
hormonal treatments and a high-fat diet (Warrier M. et al., unpublished
data). Null mice treated with dexamethasone agonist showed increased
expression of GR markers in liver, muscle and adipose. Null mice sub-
jected to a high-fat diet were dramatically resistant toweight gain, espe-
cially adipose mass, suggesting elevated GR induction of lipolysis.
However, serum glucose, fatty acid and triglyceride levels were very
low in diet challenged null mice, suggesting an additional phenotype of
heightened energy expenditure. The latter metabolic effects may arise
from FKBP51 targets other than GR. Indeed, there is recent evidence
that FKBP51 can act as a scaffolding protein that promotes Akt dephos-
phorylation by the PHLPP phosphatase [85]. Since Akt activation is criti-
cal to insulin action, most notably, promotion of glucose uptake [86], a
GR-independent role for FKBP51 appears likely in the null mice. Yet, re-
duced levels of serum corticosterone were observed in the null mice,
consistent with a state of GC hypersensitivity at peripheral organs, or in-
creased feedback suppression at the hypothalamus-pituitary-adrenal
(HPA) axis, as shown by Hartmann et al. [84].
7. PP5
7.1. Molecular actions and predicted endocrinology
Protein phosphatase 5 is a unique member of the phosphatase
family due to presence of TPR domains which allow for binding to
Hsp90 [87,88]. To date, association of PP5 with SRs has only been
demonstrated for GR and ER. Indeed, a side-by-side comparison of
co-expressed GR and PR found a distinct preference of PP5 (and
FKBP51) for GR but no detectable interaction with PR, which pre-
ferred FKBP52 [59]. More recently, a TPR peptide derived from PP5
was shown to alter the activities of PPARα and PPARγ [8], but direct
binding by intact PP5 has yet to be published. Because PP5 also affects
a host of non-SR responses, including MAPK-mediated growth, DNA
damage repair and regulation of ion channels, interpretation of re-
sults in mouse models may be difﬁcult. Indeed, because of its pleiot-
ropy, most investigators predicted that the PP5 null mouse would
be an embryonic lethal. Surprisingly, PP5 null mice were recently
generated [89], but little work on altered physiology has been done.
However, studies in PP5 KO MEF cells derived from these mice have
conﬁrmed the role of PP5 in DNA damage repair and cell cycle arrest
by attenuating the activities of two checkpoint kinases, ataxia telangi-
ectasia mutated (ATM) kinase and ATM-and-Rad3 related (ATR) ki-
nase [89]. In a different approach, transgenic mice with cardiac
myocyte-speciﬁc over-expression of PP5 have been produced, dem-
onstrating that PP5 contributes to β-adrenergic contractility of the
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tests in mice have yet to be done, but two promising directions can
be highlighted.
7.2. A role for PP5 in breast cancer?
Although a case can bemade for PP5 contribution to many types of
cancer, its potential role in breast cancer is perhaps the most compel-
ling. In addition to binding ER via Hsp90, PP5 is known to be upregu-
lated by estradiol in MCF-7 breast cancer cells and to have a
functional estrogen response element in its promoter [91,92]. Inter-
estingly, estradiol-mediated upregulation of PP5 interferes with
glucocorticoid-induced arrest of cell growth [92] due to PP5-
mediated dephosphorylation and inhibition of GR [93]. It is likely,
however, that ER induction of PP5 stimulates additional pro-growth
pathways, although these have not yet been identiﬁed. Circumstantial
evidence is growing. PP5 over-expression increased growth rates of
MCF-7 cells [91]. In xenograph models of breast cancer, over-
expression of PP5 accelerated tumor growth in response to estrogen
[94]. Immunostaining of human breast cancer tissue has revealed
high levels of PP5 in ductal carcinoma in situ, and in invasive ductal
carcinoma with or without metastases [95]. Moving forward it will
be interesting to see if transgenic over-expression of PP5 to mamma-
ry epithelia of the mouse will produce either spontaneous or induced
breast tumors with heightened sensitivity to estrogens.
7.3. Does PP5 control PPARγ induction of adipogenesis?
Ever since Chen and Cohen discovered that PP5 phosphatase activ-
ity can be activated by polyunsaturated fatty acids (e.g., arachidonic
acid), an intriguing potential role for PP5 in regulation of lipid metab-
olism has existed [96–98]. This idea was bolstered by the aforemen-
tioned interaction of PPARs with Hsp90. We have pursued this
concept by asking whether PP5 contributes to the adipogenic proper-
ties of PPARγ (Hinds T. et al., unpublished data). Wild-type and
PP5KO MEF cells were used to show that PP5-mediated dephosphor-
ylation of PPARγ at serine 112 is required for rosiglitazone activation
of PPARγ. In the absence of PP5, PPARγ could not induce expression
of pro-adipogenic genes, such as aP2 and CD36. Moreover, GR activity
at lipolytic genes was highly elevated in PP5KO cells, due to hyper-
phosphorylation at serines 212 and 234. The net effect of PP5 actions
on both targets was a near complete blockade of adipogenic differen-
tiation and lipid accumulation. Studies to conﬁrm these mechanisms
in PP5 null mice are underway.
8. Conclusion
Although the studies described above are low in number, it is al-
ready clear that mouse genetic models can provide greatly needed in-
sights into how the Hsp90 chaperone machine contributes to
steroidal control of physiology (Fig. 1). As we move forward, the
physiological effects obtained will inform how we interpret existing
molecular and cellular mechanisms. In turn, new molecular discover-
ies can be tested in vivo using the already established mouse models
and new ones to be developed. Until then, a number of perplexing is-
sues remain that are worth highlighting.
8.1. What, no compensation?
A surprising outcome of the Hsp90α and Hsp90β null mice is the
almost complete lack of compensation of one isoform for the other.
This is in spite of the overwhelming in vitro data showing more over-
lap than differences when it comes to functionality and client sub-
strate speciﬁcity. Although it could be argued that the normal
phenotypes of both Hsp90 heterozygotes are examples of compensa-
tion, it is more likely that half-gene dosage is simply enough to avoidproducing serious defects that are easy to detect. In the FKBP52 het-
erozygote null mice, no fertility problems were observed in males
or females. Because of this, we have compared TPR protein recruit-
ment to PR and GR complexes in FKBP52 KO cells and have found
no compensatory binding by FKBP51, PP5 or Cyp40 to either receptor
complex [55,59]. Moreover, it can be inferred that if compensation is
an important functional process, then compensatory increased ex-
pression of partner proteins should occur. To date, we have found
no evidence for increased expression of any TPR protein in FKBP52
KO cells or tissues. Similarly, increased expression of Hsp90β was
not seen in the Hsp90α null mice. These types of results reinforce
the notion that in vitro experiments can be ﬂawed. That is, without
the energy-driven, compartmentalized environment of cells in an en-
docrine and metabolically regulated environment, interactions can
occur in solution, or even in tissue culture cells, that never have an
opportunity in the intact cell of an organism.
8.2. Neuroendocrine vs peripheral sensitivity
Even before the ﬁrst TPR null mouse was generated, a chicken and
egg dilemma existed because SR activity is necessary for peripheral
organ sensitivity and for negative-feedback regulation of steroid se-
cretion. Using GR and FKBP52 as an example, if loss of FKBP52 were
to globally decrease GR activity in all tissues, what would be the bal-
ance between the HPA axis and peripheral organ sensitivity? Would
lack of organ sensitivity be more than compensated for by loss of
negative-feedback suppression, resulting in very high levels of secret-
ed GCs and perhaps a phenotype indicative of over-stimulation? Or
would organ insensitivity be the dominant phenotype? Moreover,
extra-endocrine steroidal synthesis is also known to occur, such as
production and secretion of GCs by several peripheral tissues [99]. Al-
though this dilemma is far from resolved, the results so far obtained
are intriguing. In the FKBP52 mutant mouse, reduced sensitivity of
the liver to GCs appears to occur, even in the presence of elevated
serum corticosterone [60]. Thus, the HPA axis is not incapable of
responding to peripheral insensitivity by increasing corticosterone
secretion. To what extent, if any, it is limited by reduced GR-
mediated feedback suppression is still unknown. In the FKBP51 null
mice, hypersensitivity to GCs at peripheral organs was expected.
The results of Schmidt and colleagues [84], and our own unpublished
data, showed low levels of serum corticosterone, indicative of an
overall GC hypersensitivity syndrome at peripheral organs and the
HPA axis. Determination of the relative contribution of each still
awaits.
8.3. The tissue proﬁle paradox
One would normally predict that the tissue expression proﬁle of a
protein would correlate with the observed phenotypes in globally ab-
lated mice. This has not been the case in chaperone null mice. A good
example of this is the FKBP52 null male, which shows penile hypo-
spadias and dysgenic prostate, yet all other genital organs developed
normally, such as testes. Testicular function was normal as measured
by sperm count, although reduced motility of sperm was observed
[61]. Yet, proﬁling of FKBP52 showed expression of the protein in all
genital organs, with testes being the highest. Thus, FKBP52 cannot
be a global and essential regulator AR, since that should lead to a phe-
notype similar to the AR null mouse, where all male genital organs are
reduced or missing, leading to a feminization syndrome [100]. Yet,
the question remains as to why AR functions are not affected by
FKBP52 loss in the testes. As discussed above, this could arise from
compensation by FKBP51, which also promotes AR activity. But in-
creased recruitment of FKBP51 to AR in FKBP52 KO cells has been
found, as well as no increase of FKBP51 expression in testes of null
mice [61]. Perhaps the function of FKBP52 in the testes is to regulate
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Fig. 1. Hsp90 TPR cochaperones differentially modulate steroid receptor activity and tissue-speciﬁc endocrine physiology. In cell-based studies, FKBP52 is typically a positive reg-
ulator of SR transcriptional activity, while FKBP51 and PP5 are negative regulators. Assuming that this relationship holds true in the mouse, phenotypes consistent with steroidal
resistance or steroidal hypersensitivity are therefore expected. The limited studies so far reported in genetically-ablated mice generally support this model. Exceptions to these
functional relationships include: positive regulation of AR by FKBP51 leading to resistance1; positive regulation of PPARγ by PP5 leading to resistance2; regulation of ER by PP5
is still not clear, yet PP5 is a highly induced target gene of ER, suggesting an overall potential phenotype of resistance in PP5 null mice2.
727E.R. Sanchez / Biochimica et Biophysica Acta 1823 (2012) 722–729another SR. If true, then tissue-speciﬁc signal pathways or processes
must exist that direct TPR proteins to one receptor over another.
In summary, these early studies using mouse genetic models of
chaperones are providing more unanswered questions than facts.
Resolution of the major issues will require the generation of tissue-
speciﬁc knockout and over-expressing mice, as well as better insights
into the potential developmental, hormonal, or even metabolic vari-
ables that impact how cochaperones acting through Hsp90 regulate
the tissue-speciﬁc responses to steroids.
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